⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMRX News
Immuneering Corporation Class A Common Stock
Form 8-K
sec.gov
IMRX
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com
IMRX
Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
globenewswire.com
IMRX
Immuneering Corporation Announces Grants of Inducement Awards
globenewswire.com
IMRX
Kalaris Appoints Laurie Keating to Board of Directors
globenewswire.com
KLRS
PEPG
IMRX
Form 8-K
sec.gov
IMRX
Immuneering Appoints Andrew Gengos as Chief Financial Officer
globenewswire.com
IMRX
Form 8-K
sec.gov
IMRX
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
globenewswire.com
IMRX
Form 8-K
sec.gov
IMRX